WO2009154695A1 - Preparation and composition of inter-alpha inhibitor proteins from blood - Google Patents

Preparation and composition of inter-alpha inhibitor proteins from blood Download PDF

Info

Publication number
WO2009154695A1
WO2009154695A1 PCT/US2009/003291 US2009003291W WO2009154695A1 WO 2009154695 A1 WO2009154695 A1 WO 2009154695A1 US 2009003291 W US2009003291 W US 2009003291W WO 2009154695 A1 WO2009154695 A1 WO 2009154695A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
buffer
wash
icdp
iaip
Prior art date
Application number
PCT/US2009/003291
Other languages
English (en)
French (fr)
Inventor
Yow-Pin Lim
Edward S. Sirya
Peter Brne
Original Assignee
Pro Thera Biologics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020167030334A priority Critical patent/KR101828433B1/ko
Priority to ES09767008.7T priority patent/ES2673005T3/es
Application filed by Pro Thera Biologics, Llc filed Critical Pro Thera Biologics, Llc
Priority to US12/995,141 priority patent/US9139641B2/en
Priority to EP09767008.7A priority patent/EP2291654B1/en
Priority to CA2726281A priority patent/CA2726281C/en
Priority to CN200980129119.6A priority patent/CN102112876B/zh
Priority to AU2009260822A priority patent/AU2009260822B2/en
Priority to BRPI0913949A priority patent/BRPI0913949A2/pt
Priority to KR1020107029406A priority patent/KR101714008B1/ko
Priority to DK09767008.7T priority patent/DK2291654T3/en
Priority to KR1020177027338A priority patent/KR20170116196A/ko
Priority to JP2011511643A priority patent/JP5793076B2/ja
Priority to BR122020017577-0A priority patent/BR122020017577B1/pt
Publication of WO2009154695A1 publication Critical patent/WO2009154695A1/en
Priority to US14/859,705 priority patent/US9758570B2/en
Priority to US15/439,328 priority patent/US10076559B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2009/003291 2008-05-28 2009-05-28 Preparation and composition of inter-alpha inhibitor proteins from blood WO2009154695A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
KR1020107029406A KR101714008B1 (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물
BRPI0913949A BRPI0913949A2 (pt) 2008-05-28 2009-05-28 preparação e composição de proteínas inibidoras inter-alfa a partir de sangue
US12/995,141 US9139641B2 (en) 2008-05-28 2009-05-28 Preparation and composition of inter-alpha proteins from blood
ES09767008.7T ES2673005T3 (es) 2008-05-28 2009-05-28 Preparación y composición de proteínas inter-alfa inhibidoras a partir de sangre
CA2726281A CA2726281C (en) 2008-05-28 2009-05-28 Preparation and composition of inter-alpha inhibitor proteins from blood
CN200980129119.6A CN102112876B (zh) 2008-05-28 2009-05-28 来自血液的间‑α抑制物蛋白的制备和组合物
DK09767008.7T DK2291654T3 (en) 2008-05-28 2009-05-28 PREPARATION AND COMPOSITION OF BLOOD INTER-ALPHA INHIBITOR PROTEINS
KR1020167030334A KR101828433B1 (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물
EP09767008.7A EP2291654B1 (en) 2008-05-28 2009-05-28 Preparation and composition of inter-alpha inhibitor proteins from blood
AU2009260822A AU2009260822B2 (en) 2008-05-28 2009-05-28 Preparation and composition of Inter-alpha inhibitor proteins from blood
KR1020177027338A KR20170116196A (ko) 2008-05-28 2009-05-28 혈액으로부터 인터-알파 저해 단백질의 제조 및 조성물
JP2011511643A JP5793076B2 (ja) 2008-05-28 2009-05-28 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
BR122020017577-0A BR122020017577B1 (pt) 2008-05-28 2009-05-28 Método para purificar proteínas inibidoras inter-alfa
US14/859,705 US9758570B2 (en) 2008-05-28 2015-09-21 Preparation and composition of inter-alpha inhibitor proteins from blood
US15/439,328 US10076559B2 (en) 2008-05-28 2017-02-22 Preparation and composition of inter-alpha inhibitor proteins from blood

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13026908P 2008-05-28 2008-05-28
US61/130,269 2008-05-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/995,141 A-371-Of-International US9139641B2 (en) 2008-05-28 2009-05-28 Preparation and composition of inter-alpha proteins from blood
US14/859,705 Division US9758570B2 (en) 2008-05-28 2015-09-21 Preparation and composition of inter-alpha inhibitor proteins from blood

Publications (1)

Publication Number Publication Date
WO2009154695A1 true WO2009154695A1 (en) 2009-12-23

Family

ID=41434346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/003291 WO2009154695A1 (en) 2008-05-28 2009-05-28 Preparation and composition of inter-alpha inhibitor proteins from blood

Country Status (13)

Country Link
US (3) US9139641B2 (zh)
EP (1) EP2291654B1 (zh)
JP (3) JP5793076B2 (zh)
KR (3) KR101714008B1 (zh)
CN (2) CN106928346B (zh)
AU (1) AU2009260822B2 (zh)
BR (2) BR122020017577B1 (zh)
CA (1) CA2726281C (zh)
DK (1) DK2291654T3 (zh)
ES (1) ES2673005T3 (zh)
PT (1) PT2291654T (zh)
TR (1) TR201808152T4 (zh)
WO (1) WO2009154695A1 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012773A1 (en) 2010-07-23 2012-01-26 Baxter International Inc. Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
US9468675B2 (en) 2010-05-26 2016-10-18 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
EP3048899A4 (en) * 2013-09-25 2017-08-02 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US9758570B2 (en) 2008-05-28 2017-09-12 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from blood
USRE47972E1 (en) 2003-11-08 2020-05-05 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
US11136350B2 (en) 2010-05-26 2021-10-05 Takeda Pharmaceutical Company Limited Method to produce an immunoglobulin preparation with improved yield
WO2022104282A1 (en) 2020-11-16 2022-05-19 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101443257B1 (ko) * 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
ES2737078T3 (es) * 2013-09-04 2020-01-10 Emd Millipore Corp Cromatografía de Proteína A
CN104138374A (zh) * 2014-07-26 2014-11-12 滨州医学院 硫酸阿扎那韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用
EP3362464B1 (en) * 2015-10-15 2021-04-28 Plasma Technologies LLC Methods for extracting proteins from blood plasma
BR112019022358A2 (pt) * 2017-04-25 2020-05-19 Prothera Biologics Inc métodos para quantificar proteínas inibidoras inter-alfa
EP3714036A1 (en) * 2017-11-20 2020-09-30 Lonza Ltd Process and system for propagating cell cultures while preventing lactate accumulation
WO2020086879A1 (en) * 2018-10-24 2020-04-30 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
CN109900689B (zh) * 2019-03-28 2021-12-10 复星诊断科技(长沙)有限公司 抗干扰膜及肝功能联合测试条
WO2023089503A1 (en) * 2021-11-16 2023-05-25 Takeda Pharmaceutical Company Limited Inter-alpha inhibitor protein formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070297982A1 (en) 2003-11-08 2007-12-27 Prothera Biologics Preparation And Composition Of Inter-Alpha Inhibitor Proteins From Human Plasma For Therapeutic Use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839298A (en) * 1986-02-14 1989-06-13 Akzo N.V. Virus inactivating diluents used in immunoassays
ATE100210T1 (de) 1988-11-01 1994-01-15 Sanol Arznei Schwarz Gmbh Lyophilisiertes mdm enthaltende zusammensetzung und verfahren zu deren herstellung.
GB8928501D0 (en) 1989-12-18 1990-02-21 Unilever Plc Reagents
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
JPH0953775A (ja) 1995-06-09 1997-02-25 Kubota Corp 埋設管路
WO1997004075A1 (en) * 1995-07-20 1997-02-06 New York University Pharmaceutical compositions containing tsg-6 for treating inflammatory diseases and cancer-related pathologies and methods
JP2002521055A (ja) 1998-07-30 2002-07-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９８個のヒト分泌タンパク質
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6489128B1 (en) 2000-01-24 2002-12-03 Rhode Island Hospital, A Lifespan Partner Methods for detecting cancer of the central nervous system
US6660482B1 (en) 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
US20030190732A1 (en) 2000-10-13 2003-10-09 Djuro Josic Plasma fraction containing bikunin, method for the production thereof and use of the same
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
ES2269509T3 (es) 2000-12-08 2007-04-01 Genentech, Inc. Gen expresado altamente en el tejido cartilaginoso.
GB0114709D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Stabilised formulations of amlodipine maleate
US20030027848A1 (en) 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
US20040009212A1 (en) * 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
MXPA04009385A (es) 2002-03-26 2005-01-25 Teva Pharma Microparticulas de drogas.
NZ542303A (en) * 2003-03-14 2008-12-24 Nirmal Mulye A process for preparing sustained release tablets
CA2538737A1 (en) 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-il-2 receptor antibodies
EP1765866B1 (en) 2004-06-07 2014-01-08 Therapure Biopharma Inc. Isolation of plasma or serum proteins
US7939282B2 (en) 2004-10-21 2011-05-10 Rhode Island Hospital Methods for detecting sepsis
CN101160133B (zh) 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
US8153162B2 (en) 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US7390786B2 (en) 2005-12-21 2008-06-24 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2008067655A1 (en) 2006-12-05 2008-06-12 Q6 Biomaterials Inc. Biocompatible hydrogel-based scaffolds
ES2673005T3 (es) 2008-05-28 2018-06-19 Prothera Biologics, Inc Preparación y composición de proteínas inter-alfa inhibidoras a partir de sangre
EP2313106B1 (en) 2008-07-18 2016-03-30 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
CA2743768A1 (en) 2008-12-10 2010-06-17 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US9562906B2 (en) 2010-06-10 2017-02-07 National University Of Singapore Methods for detection of gastric cancer
JP5830096B2 (ja) 2010-07-23 2015-12-09 バクスター、インターナショナル、インコーポレイテッド 血漿由来インターα阻害タンパク質（ＩａＩｐ）の製造方法
AU2013312215C1 (en) 2012-09-09 2018-09-06 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070297982A1 (en) 2003-11-08 2007-12-27 Prothera Biologics Preparation And Composition Of Inter-Alpha Inhibitor Proteins From Human Plasma For Therapeutic Use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIM ET AL., J. CHROMATOGRAPHY A, vol. 1065, 2005, pages 39 - 43
LIM ET AL.: "Affinity purification and enzymatic cleavage of inter-alpha inhibitor proteins using antibody and elastase immobilized on CIM monolithic disks", JOURNAL OF CHROMATOGRAPHY A, vol. 1065, 2005, pages 39 - 43, XP004750089 *
LIM, INTER-ALPHA INHIBITORS: FROM LABORATORY TO MARKET, 16 February 2006 (2006-02-16)
See also references of EP2291654A4

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47972E1 (en) 2003-11-08 2020-05-05 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
US9758570B2 (en) 2008-05-28 2017-09-12 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from blood
US10076559B2 (en) 2008-05-28 2018-09-18 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from blood
US10875906B2 (en) 2010-05-26 2020-12-29 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US11891431B2 (en) 2010-05-26 2024-02-06 Takeda Pharm Limited ceutical Company Limited Removal of serine proteases by treatment with finely divided silicon dioxide
US9708391B2 (en) 2010-05-26 2017-07-18 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US11136350B2 (en) 2010-05-26 2021-10-05 Takeda Pharmaceutical Company Limited Method to produce an immunoglobulin preparation with improved yield
US10208106B2 (en) 2010-05-26 2019-02-19 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US9468675B2 (en) 2010-05-26 2016-10-18 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US20120053113A1 (en) * 2010-07-23 2012-03-01 Baxter Healthcare S.A. MANUFACTURE OF INTER-ALPHA-INHIBITOR (IaIp) FROM PLASMA
US9505814B2 (en) 2010-07-23 2016-11-29 Baxalta Incorporated Manufacture of inter-alpha-inhibitor (IaIp) from plasma
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma
JP2013535468A (ja) * 2010-07-23 2013-09-12 バクスター、インターナショナル、インコーポレイテッド 血漿由来インターα阻害タンパク質（ＩａＩｐ）の製造方法
WO2012012773A1 (en) 2010-07-23 2012-01-26 Baxter International Inc. Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
US10258675B2 (en) 2012-09-09 2019-04-16 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3048899A4 (en) * 2013-09-25 2017-08-02 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3903599A1 (en) * 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US11578098B2 (en) 2013-09-25 2023-02-14 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2022104282A1 (en) 2020-11-16 2022-05-19 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins

Also Published As

Publication number Publication date
US20160145318A1 (en) 2016-05-26
CN102112876A (zh) 2011-06-29
CA2726281A1 (en) 2009-12-23
CN102112876B (zh) 2017-12-08
KR101714008B1 (ko) 2017-03-09
BRPI0913949A2 (pt) 2015-10-20
KR20160129914A (ko) 2016-11-09
JP6309915B2 (ja) 2018-04-11
CA2726281C (en) 2023-04-18
EP2291654B1 (en) 2018-04-11
JP2015155434A (ja) 2015-08-27
US9139641B2 (en) 2015-09-22
DK2291654T3 (en) 2018-06-14
US9758570B2 (en) 2017-09-12
EP2291654A4 (en) 2011-08-24
JP2011524343A (ja) 2011-09-01
TR201808152T4 (tr) 2018-07-23
ES2673005T3 (es) 2018-06-19
CN106928346A (zh) 2017-07-07
JP2018008941A (ja) 2018-01-18
PT2291654T (pt) 2018-06-15
AU2009260822A1 (en) 2009-12-23
AU2009260822B2 (en) 2016-09-22
BR122020017577B1 (pt) 2021-10-26
US10076559B2 (en) 2018-09-18
KR101828433B1 (ko) 2018-03-29
US20110190194A1 (en) 2011-08-04
JP5793076B2 (ja) 2015-10-14
CN106928346B (zh) 2021-09-07
US20170157224A1 (en) 2017-06-08
KR20170116196A (ko) 2017-10-18
KR20110053404A (ko) 2011-05-23
EP2291654A1 (en) 2011-03-09

Similar Documents

Publication Publication Date Title
US10076559B2 (en) Preparation and composition of inter-alpha inhibitor proteins from blood
US8415293B2 (en) Peptide mediators of cholesterol efflux
JP5010920B2 (ja) 治療に使用するためのヒト血漿由来のインターα阻害タンパク質の調製方法及びその組成物
US8987192B2 (en) Potent and selective mediators of cholesterol efflux
CN101160133A (zh) 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980129119.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09767008

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2726281

Country of ref document: CA

Ref document number: 2011511643

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009767008

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009260822

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20107029406

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009260822

Country of ref document: AU

Date of ref document: 20090528

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12995141

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0913949

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101129